Triple combination therapy shows promise against a rare deadly asbestos cancer
(University Health Network) Combining immune-boosting drugs with radiation and surgery increased the survival and anticancer immune response in mouse models of mesothelioma in preclinical research by Princess Margaret Cancer Centre researchers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 14, 2021 Category: Cancer & Oncology Source Type: news

Latest KCIC Report Finds Decline in Mesothelioma Lawsuits
The number of mesothelioma lawsuits filed in 2020 dropped significantly, while cases involving lung cancer continued to increase, according to a recent study reflecting the changing face of asbestos litigation. KCIC, a well-respected consulting firm in Washington, D.C., that manages asbestos product liabilities, released its industry report Thursday. Asbestos legal filings, covering both malignant and nonmalignant disease in the United States, dropped 11% from 2019 to 2020, from 4,137 to 3,685 cases, respectively. Most prominently, there was a 9% increase in asbestos-related lung cancer filings, but a 14% decrease...
Source: Asbestos and Mesothelioma News - April 12, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news

Phase III Trial of Durvalumab for Mesothelioma Underway
The U.S. Food and Drug Administration will be closely watching the latest, international phase III clinical trial for unresectable pleural mesothelioma involving the immunotherapy drug durvalumab. FDA approval may be coming soon. “It looks very promising,” Dr. Arkadiusz Dudek, of Regions Hospital Cancer Care Center in St. Paul, Minnesota, told The Mesothelioma Center at Asbestos.com. “The hope is to have the regimen approved by the FDA as front-line therapy. There is a real need today for more options with mesothelioma.” The goal of the randomized trial – officially known as DREAM3R &...
Source: Asbestos and Mesothelioma News - April 1, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

COVID Vaccine Gives Less Protection for Some Cancer Patients
Millions of people across the United States have begun receiving their COVID-19 vaccines, and restrictions are lifting in many public spaces such as restaurants and bars. Mesothelioma patients may be looking forward to returning to life as it was before the pandemic. However, a new study reports that the COVID-19 vaccine may not sufficiently protect patients with compromised or weakened immune systems. The study results suggest that people with cancer or who are undergoing cancer treatment may still be highly vulnerable to COVID-19 even after their vaccination. Researchers published their findings earlier this m...
Source: Asbestos and Mesothelioma News - March 30, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Thoracic Surgeon Raja Flores Enters NYC Mayor ’s Race
Thoracic surgeon and mesothelioma specialist Dr. Raja Flores wants to continue serving others, but in a new role as the next mayor of New York City. “Yes, I’m serious about this. Very serious,” Flores told The Mesothelioma Center at Asbestos.com Tuesday after another 14-hour workday and an evening surgery at Mount Sinai. “I want to take care of this city that has taken such good care of me.” Flores, the esteemed chairman of thoracic surgery at Mount Sinai Hospital, filed his official eligibility petition last week with the New York City Board of Elections. He listed himself as an inde...
Source: Asbestos and Mesothelioma News - March 25, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news

Some Mesothelioma Patients May Benefit from Second Radical Surgery
This study should elicit a call of hands for centers to share their experiences, to say either do it, or not do it,” Elsayed said. “Right now, you just don’t find a good number of centers doing that second operation.” Earlier Mesothelioma Surgery Studies  This most recent report focused on three smaller studies totaling 40 patients involved in a second major surgery with a curative intent for mesothelioma. In the first group of 16 patients, there was a median survival of 20.4 months after the second surgery for those with epithelial cell type, but only 7.4 months survival for those wit...
Source: Asbestos and Mesothelioma News - March 17, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Durvalumab immunotherapy proceeds to phase 3 trial for malignant pleural mesothelioma
(ECOG-ACRIN Cancer Research Group) The DREAM3R phase 3 clinical trial is now enrolling patients with newly diagnosed unresectable malignant pleural mesothelioma (MPM) throughout the US, Australia, and New Zealand. DREAM3R aims to enroll 480 patients with non-epithelioid or epithelioid subtype. Patients will be randomized 2:1 to receive durvalumab immunotherapy plus 4-6 cycles of chemotherapy or chemotherapy alone. Patients in the experimental group will continue to receive durvalumab after chemotherapy until disease progression, unacceptable toxicity, or patient withdrawal. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 17, 2021 Category: International Medicine & Public Health Source Type: news

U.S. Asbestos Imports Increased Significantly in 2020
An estimated 300 metric tons of raw chrysotile asbestos was imported into the U.S. in 2020, almost doubling the amount from 2019, according to the recent United States Geological Survey Mineral Commodity Summaries report. The chloralkali industry accounted for 100% of the imports, all from Brazil. This industry uses the asbestos in the manufacturing of semipermeable diaphragms for making chlorine. Asbestos import numbers were the second smallest in more than 50 years and only a fraction of the all-time high of 803,000 tons reported in 1973. Also imported into the United States, but not included in the report, is a...
Source: Asbestos and Mesothelioma News - March 15, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

New Link Between Women with Mesothelioma and Survival Genes
Men with mesothelioma outnumber women four to one. However, numerous studies have shown that women with mesothelioma often have a survival advantage over men. Now, scientists might have a better understanding of why. Researchers have identified a gene that predicts the prognosis and treatment outcome for women with malignant pleural mesothelioma. The research took place as part of the International Mesothelioma Program at Brigham and Women’s Hospital in Boston. Dr. Assunta De Rienzo led the new study after years of research highlighting the sex-based disparity among mesothelioma patients. “The goal is ...
Source: Asbestos and Mesothelioma News - March 10, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Legal Fight Continues Over Asbestos Disease in Libby, Mont.
The Center for Asbestos Related Disease in Libby, Montana, dodged a potential setback recently when officials from the U.S. Department of Justice decided against joining a lawsuit alleging fraudulent medical practices. Burlington Northern Santa Fe Railway filed the original suit in 2019 against the center – known as the CARD Clinic – alleging Medicare fraud that included unnecessary screenings and misdiagnosing patients with various asbestos-related diseases. The railroad giant is facing more than a thousand asbestos-related injury claims stemming from its transportation of asbestos-laden products through its r...
Source: Asbestos and Mesothelioma News - March 5, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Johnson & Johnson Preparing $3.9 Billion for Talc Settlements
Pharmaceutical giant Johnson & Johnson has set aside $3.9 billion for talc-related litigation, according to a regulatory filing this week with the Securities and Exchange Commission in Washington D.C. The company said it’s now facing more than 25,000 lawsuits related to various talc products that have allegedly caused cancers, primarily from asbestos fiber contamination. The $3.9 billion is almost double the amount that Johnson & Johnson reported being set aside for litigation expenses in its 2020 fiscal year-end results. A Missouri Court of Appeals earlier last year upheld a lower-court ruling, but reduced t...
Source: Asbestos and Mesothelioma News - February 24, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news

Study: Which Mesothelioma Patients Will Immunotherapy Benefit?
This study also is designed to better understand the biological mechanisms affecting the immune system. The goal is to use both the cellular organization and molecular pathways to develop a test that can predict the response to the checkpoint inhibitor drugs. Upon completion, a clinical trial would follow, in which treatment would depend on the results of the individual’s test. “Within the next year or two, we’ll have a good idea of whether these components are working,” Burt said. The post Study: Which Mesothelioma Patients Will Immunotherapy Benefit? appeared first on Mesothelioma Center - Vital S...
Source: Asbestos and Mesothelioma News - February 23, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news

Winter Storm Delays Cancer Treatment Across U.S.
Severe winter storms have affected multiple central U.S. states with power outages and water supply disruptions. State officials in Texas, Louisiana and Mississippi say restoring power to everyone could still take several days. Over the past week, problems with state infrastructure left millions of residents across Texas and Oklahoma without heat and potable water. Dr. Raja Flores, a thoracic surgeon at Mount Sinai Cancer Center in New York, says the weather has also affected cancer patients in his area. “With the storm, many services are not available,” Dr. Flores told The Mesothelioma Center at Asbestos.com. ...
Source: Asbestos and Mesothelioma News - February 22, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news

FDA Fast-Tracks Mesothelioma Vaccine Development
The U.S. Food and Drug Administration has granted Fast-Track Designation this week to ONCOS-102, an immunotherapy vaccine that targets malignant mesothelioma and other hard-to-treat tumors. This designation is expected to expedite the regulatory approval process. The vaccine’s developer, Targovax, a small biotech company that focuses on oncolytic viruses, sees this as an early endorsement from the FDA. “Yes, this opens the door for us,” Dr. Magnus Jaderberg, chief medical officer of Targovax, told The Mesothelioma Center at Asbestos.com. “It validates what the FDA believes is a potentially promising...
Source: Asbestos and Mesothelioma News - February 19, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news

Study seeks to identify biological markers that predict mesothelioma response to treatment
(Baylor College of Medicine) The goal of this study is to develop a clinically relevant test that would enable physicians to determine whether a patient would be most likely or less likely to respond to a form of immunotherapy before the patient gets treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 16, 2021 Category: Cancer & Oncology Source Type: news

Research Reinforces Gene Mutation Links to Mesothelioma
More than ever, Dr. Michele Carbone at the University of Hawaii Cancer Center believes early testing for genetic mutations can lead to fewer cases of malignant mesothelioma and a longer survival time for many who do contract the disease. Lives can be saved. Years can be added. “It could change the way we treat these patients,” Carbone told The Mesothelioma Center at Asbestos.com. “And, in some cases, it could prevent the cancer entirely.” Carbone is director of thoracic oncology at University of Hawaii and a world leader in identifying the role of genetics in the development of mesothelioma cancer. ...
Source: Asbestos and Mesothelioma News - February 11, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Mesothelioma Still Prevalent in Canada Following Asbestos Ban
More than two years after implementing a much-celebrated ban of asbestos, Canadians have come to realize the real fight has only just begun. Malignant mesothelioma cancer isn’t going away any time soon. Asbestos exposure may be the only confirmed cause of mesothelioma, but the nationwide ban of the toxic mineral is not predicted to slow the rise in cases for decades. It is expected to change the face of those being diagnosed. “It’s going to be awhile before we see any major decline in numbers,” Dr. Paul Demers, director of the Occupational Cancer Research Centre at Ontario Health, told The Mesotheli...
Source: Asbestos and Mesothelioma News - February 8, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Opdivo Study Offers Hope to Relapsed Mesothelioma Patients
A recent study out of the United Kingdom finds patients with relapsed malignant mesothelioma can be treated effectively with single-agent nivolumab, safely improving overall and progression-free survival. Nivolumab, also known by the brand name Opdivo, is an immunotherapy drug already being used successfully with non-small cell lung cancer. It is the first drug to show a significant survival advantage for relapsed mesothelioma in a phase III clinical trial, according to principal investigator Dr. Dean Fennell, medical oncologist at the University of Leicester in England. “This is very encouraging news,” Fennell...
Source: Asbestos and Mesothelioma News - February 4, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Researchers: Mesothelioma Trials Need More Inclusive Criteria
Clinical trials for mesothelioma need more inclusive criteria to better reflect the patients being seen at major cancer treatment centers, according to a recent study conducted in Sydney, Australia. The study demonstrated a significant difference between those carefully selected for clinical trials and real-world patients with pleural mesothelioma. “A broader patient population more resembling real life would be able to access the novel treatment early,” Dr. Steven Kao, medical oncologist at Chris O’Brien Lifehouse hospital and one of the study authors, told The Mesothelioma Center at Asbestos.com. &ldquo...
Source: Asbestos and Mesothelioma News - February 2, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Nivolumab Improves Survival in Relapsed Mesothelioma Nivolumab Improves Survival in Relapsed Mesothelioma
In the first placebo-controlled phase 3 trial in relapsed mesothelioma, immunotherapy with nivolumab showed a significant improvement in survival.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 2, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New weapon in battle with cancer caused by asbestos
Results from a trial show the drug nivolumab can help keep the aggressive disease mesothelioma at bay for months or even years. (Source: the Mail online | Health)
Source: the Mail online | Health - January 30, 2021 Category: Consumer Health News Source Type: news

Nivolumab effective treatment for malignant mesothelioma
(International Association for the Study of Lung Cancer) Nivolumab monotherapy is an effective treatment option for relapsed malignant mesothelioma (MM), according to research presented today at the International Association for the Study of Lung Cancer World Conference on Lung Cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 30, 2021 Category: Cancer & Oncology Source Type: news

EPA ’s Asbestos Risk Evaluation Faces Litigation
The Asbestos Disease Awareness Organization continued its challenge of the U.S. Environmental Protection Agency, filing a petition for review Jan. 26 in the U.S. Court of Appeals for the Ninth Circuit and an intent to sue notice under the Toxic Substances Control Act. ADAO, the leading nonprofit aimed at preventing asbestos exposure and raising awareness about mesothelioma, was joined by five public health groups and six doctors and scientists in its latest filings. The petition for review is aimed at the EPA’s Final Risk Evaluation for Asbestos from earlier this month that was roundly criticized for underestimating ...
Source: Asbestos and Mesothelioma News - January 27, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Study: Mesothelioma Survival Rates Rise with SMART Protocol
Using accelerated high-dose radiation prior to surgery produced an unprecedented 65.9-month median survival for a cohort of pleural mesothelioma patients who were part of a larger clinical trial at the Princess Margaret Cancer Centre in Toronto. Lancet Oncology recently published results of the study, named SMART, an acronym for Surgery for Mesothelioma After Radiation Therapy. The SMART study involved 96 patients with pleural mesothelioma who were treated in Toronto from 2008 to 2019. All received the intensity-modulated radiotherapy before extrapleural pneumonectomy surgery, an unconventional treatment regimen. Among the...
Source: Asbestos and Mesothelioma News - January 21, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Thoracic Chemotherapy May Advance Mesothelioma Treatment
Thoracic surgeon Dr. Marcello Migliore is convinced that adding hyperthermic intrathoracic chemotherapy to aggressive surgery can extend survival significantly for patients with pleural mesothelioma cancer. He wants others to know that, too. This seldom-used, controversial procedure, also known as HITHOC, involves circulating a heated, high-concentration chemotherapy solution throughout the chest cavity for 60 minutes immediately following aggressive mesothelioma surgery. The idea is to kill any microscopic tumor cells that evaded the surgeon, hopefully slowing a potential cancer recurrence. Unlike HIPEC, a similar procedu...
Source: Asbestos and Mesothelioma News - January 19, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Statins May Give Boost to Mesothelioma Immunotherapy Drugs
This study, which included both patients with pleural mesothelioma and with advanced non-small cell lung cancer, found a potential synergy with the immunotherapy drugs. Opdivo and Keytruda, generically called nivolumab and pembrolizumab, respectively, are known as PD-1 inhibitors, drugs that restrict a protein from stopping immune response to cancer cells. “Statins may lead to prolonged antigen retention on cell membrane and strengthen antigen presentation to T cells, thus suggesting a potential synergy with PD-1 inhibitors,” the authors wrote. “The anti-tumor effect of statins might be attributed to an i...
Source: Asbestos and Mesothelioma News - January 7, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

EPA Evaluation Finds Asbestos Still An Unreasonable Risk
The U.S. Environmental Protection Agency released Part 1 of its Final Risk Evaluation for Asbestos, reaffirming preliminary findings from March that were roundly criticized for underestimating the dangers of exposure to this toxic mineral. Six ongoing use categories of asbestos were evaluated by the EPA, which found 16 conditions of use that presented unreasonable risk to human health through either occupational exposures or consumer uses. Part 1 of the evaluation, released in late December 2020, involved the chrysotile type of asbestos. Chrysotile is the only type of asbestos being imported, processed or distributed for u...
Source: Asbestos and Mesothelioma News - January 6, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

What Is the Main Cause of Mesothelioma
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - December 30, 2020 Category: General Medicine Source Type: news

Judge Rules EPA Must Tighten Asbestos Data Collection
United States District Judge Edward Chen has ordered the Environmental Protection Agency to improve its data collection on the amount of asbestos and asbestos products that are coming into the country. Chen issued his ruling Tuesday in San Francisco, stemming from a lawsuit brought against the EPA by a group of nonprofit organizations wanting to close the current asbestos reporting loopholes. The EPA has contended that the voluntary reporting today by manufacturers, processors and importers provided adequate data. “EPA has not articulated a satisfactory explanation for its decision not to use its significant enforcem...
Source: Asbestos and Mesothelioma News - December 23, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Top 10 Mesothelioma and Asbestos News Stories of 2020
Growing allegations of asbestos-contaminated talc in various consumer products, coupled with historic approval of a new treatment for pleural mesothelioma, made 2020 a year filled with both anxiety and hope. Johnson & Johnson stopped selling its iconic baby powder in May after being hit by thousands of lawsuits contending its talc-based product was causing various cancers, including ovarian cancer and malignant mesothelioma. The U.S. Food and Drug Administration approved the immunotherapy combination of Opdivo and Yervoy in October, the first new drug regimen approved for first-line treatment of unresectable disease in...
Source: Asbestos and Mesothelioma News - December 15, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Differentiation of the Cs in lung cancer: Cancer vs. COVID, British Thoracic Society
Urgent referrals for cancer in general and for lung cancer specifically have fallen during the COVID-19 pandemic that will likely lead to an increase in mortality and morbidity from lung cancer. The appendix reproduces a submission by the Clinical Expert Group for lung cancer and mesothelioma which includes recommendations about differentiation of symptoms from lung cancer from those due to COVID-19 and recommendations for easy access of patients with concerning symptoms for assessment by primary care. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 3, 2020 Category: Consumer Health News Source Type: news

Study: Immunotherapy Vaccine for Mesothelioma Still Promising
The ONCOS-102 immunotherapy vaccine continues its move toward future, first-line standard of care treatment for malignant pleural mesothelioma, based upon the latest study follow-up data. When combined with standard chemotherapy, the genetically modified adenovirus has produced a median overall survival of at least 18.2 months, according to results released in late November from the ongoing clinical trial. Median overall survival was more than four months better than the control group receiving chemotherapy alone in the randomized trial. ONCOS-102 is manufactured by Targovax, a small Scandinavian biotech company focused on...
Source: Asbestos and Mesothelioma News - December 3, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Mesothelioma Patient Research Expanding in United Kingdom
The University of Sheffield has launched the Mesothelioma UK Research Centre-Sheffield, the country’s first experience-based program designed to improve the treatment and care of patients diagnosed with this aggressive, asbestos-related cancer. Based in South Yorkshire, England, the University of Sheffield hopes to become an international pioneer in patient-led mesothelioma research. “The program will build on our legacy of research from a number of years,’’ Dr. Clare Gardiner, of the University of Sheffield Health Sciences School and program co-director, told The Mesothelioma Center at Asbestos.co...
Source: Asbestos and Mesothelioma News - November 30, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Mesothelioma Surgery with Organ Removal Extends Survival
Removing major organs to achieve a more complete cancer resection did not increase severe complications or hinder survival benefits of aggressive surgery for patients with peritoneal mesothelioma, according to a recent report. The increased complexity of organ resection surgery will not adversely affect long-term outcomes, according to the multicenter study published in Annals of Surgical Oncology. By comparison, an incomplete cytoreduction that can spare the organs is associated with increased mortality and shorter overall survival. The study, which involved 174 patients across 12 specialty centers within the U.S., accent...
Source: Asbestos and Mesothelioma News - November 17, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

MRI May Best CT for Assessing Mesothelioma Tumor Volume MRI May Best CT for Assessing Mesothelioma Tumor Volume
MRI offers advantages over CT for assessing primary-tumor volume in patients with mesothelioma, researchers from UK report.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - November 9, 2020 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Trial targets deadly lung cancer
(Flinders University) With more than 650 Australians diagnosed with malignant mesothelioma last year, Flinders University is leading new research to discover alternatives to chemotherapy and even prevent deaths by early detection in future. One novel approach, using natural therapeutic benefits of curcumin, a key component of the spice turmeric, will be put to the test in a clinical trial in 2021 as part of world-leading research at Flinders University. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 30, 2020 Category: Cancer & Oncology Source Type: news

Tiny golden bullets could help tackle asbestos-related cancers
(University of Cambridge) Gold nanotubes - tiny hollow cylinders one thousandth the width of a human hair - could be used to treat mesothelioma, a type of cancer caused by exposure to asbestos, according to a team of researchers at the Universities of Cambridge and Leeds. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 26, 2020 Category: Cancer & Oncology Source Type: news

Latest T-Cell Clinical Trial Opens for Mesothelioma Patients
Memorial Sloan Kettering Cancer Center in New York City has begun recruiting patients with pleural mesothelioma for its latest — and potentially most promising — clinical trial involving T-cell therapy. The novel study stems from the U.S. Food and Drug Administration’s recent Investigational Drug Application approval of ATA2271, a chimeric antigen receptor known as CAR T-cell therapy. This latest therapy will be tested in a phase I, dose-escalation clinical trial. It will involve the removal and genetic modification of a patient’s T cells, a type of white blood cell, that will be separated in the la...
Source: Asbestos and Mesothelioma News - October 8, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Congress Fails to Vote on Asbestos Ban Legislation
The U.S. House of Representatives last week failed to advance once-promising legislation that effectively would have banned asbestos, frustrating advocates once again. H.R. 1603, titled the Alan Reinstein Ban Asbestos Now Act of 2020, had been expected to pass easily under a Congressional procedure reserved for broadly supported, non-controversial legislation. The bipartisan House Committee on Energy and Commerce had voted earlier, 47-1, to move it forward, fueling considerable optimism leading into the latest Congressional session. If passed, the bill would have then moved to the U.S. Senate, which also had shown bipartis...
Source: Asbestos and Mesothelioma News - October 7, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Johnson & Johnson Settles 1K Baby Powder-Asbestos Lawsuits
Pharmaceutical giant Johnson & Johnson has agreed to pay more than $100 million to settle an more than a thousand lawsuits claiming its iconic baby powder caused cancer, according to Bloomberg News. The settlement stems from burgeoning litigation after earlier asbestos-contaminated talc was found in one of its products. Johnson & Johnson, the world’s largest maker of health care merchandise, recalled 33,000 bottles of its baby powder in 2019, “out of an abundance of caution.” It also stopped selling talc-based baby powder the same year in the United States and Canada, switching to a cornstarch-ba...
Source: Asbestos and Mesothelioma News - October 6, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Johnson & Johnson Will Pay $100M in Baby Powder Lawsuits
Pharmaceutical giant Johnson & Johnson has agreed to pay more than $100 million to settle more than a thousand lawsuits claiming its iconic talc-based baby powder caused cancer, according to Bloomberg News. The settlement stems from burgeoning litigation after earlier asbestos-contaminated talc was found in one of its products. Johnson & Johnson, the world’s largest maker of health care merchandise, recalled 33,000 bottles of its baby powder in 2019, “out of an abundance of caution.” It also stopped selling talc-based baby powder the same year in the United States and Canada, switching to a corns...
Source: Asbestos and Mesothelioma News - October 6, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Drug Combo Approved for First-Line Treatment of Mesothelioma
Title: Drug Combo Approved for First-Line Treatment of MesotheliomaCategory: Health NewsCreated: 10/5/2020 12:00:00 AMLast Editorial Review: 10/6/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 6, 2020 Category: Cancer & Oncology Source Type: news

Drug Combo Approved for First - Line Treatment of Mesothelioma
Opdivo - Yervoy combination approved to treat adults with unresectable malignant pleural mesothelioma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 6, 2020 Category: Cancer & Oncology Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news

Drug Combo Approved for First-Line Treatment of Mesothelioma
MONDAY, Oct. 5, 2020 -- On Friday, the U.S. Food and Drug Administration announced the approval of a drug combination for first-line treatment of unresectable malignant pleural mesothelioma (MPM) -- the first drug regimen to be approved for... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 5, 2020 Category: General Medicine Source Type: news

FDA Approves Opdivo, Yervoy Combination for Mesothelioma
The U.S. Food and Drug Administration has approved the immunotherapy combination of Opdivo and Yervoy for first-line treatment of unresectable malignant pleural mesothelioma. It was the first new drug regimen approved for mesothelioma in 16 years and only the second systemic therapy ever. The historic treatment approval for this cancer without a cure was the first since the FDA approved the chemotherapy combination of pemetrexed and cisplatin in 2004. “This marks the beginning of a new era for mesothelioma,” Dr. Bernardo Goulart, medical oncologist at Seattle Cancer Care Alliance, told The Mesothelioma Center a...
Source: Asbestos and Mesothelioma News - October 5, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

FDA Approves Opdivo, Yervoy Combination for Mesothelioma
The U.S. Food and Drug Administration has approved the immunotherapy combination of Opdivo and Yervoy for first-line treatment of unresectable malignant pleural mesothelioma. It was the first new drug regimen approved for mesothelioma in 16 years and only the second systemic therapy ever. The historic treatment approval for this cancer without a cure was the first since the FDA approved the chemotherapy combination of pemetrexed and cisplatin in 2004. “This marks the beginning of a new era for mesothelioma,” Dr. Bernardo Goulart, medical oncologist at Seattle Cancer Care Alliance, told The Mesothelioma Center a...
Source: Asbestos and Mesothelioma News - October 5, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

FDA OKs Combo Therapy for First-Line Mesothelioma Treatment FDA OKs Combo Therapy for First-Line Mesothelioma Treatment
Combination nivolumab and ipilimumab has now been approved as first-line treatment in mesothelioma and possibly a new standard of care.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 3, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma
PRINCETON, N.J.--(BUSINESS WIRE) October 2, 2020 -- Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg every three weeks plus Yervoy (ipilimumab) 1 mg/kg every six weeks (injections for intravenous use) was approved by... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 2, 2020 Category: Drugs & Pharmacology Source Type: news

FDA approves nivolumab and ipilimumab for unresectable malignant pleural mesothelioma
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 2, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news